Last reviewed · How we verify
ETN+MTX
ETN+MTX is a combination therapy of etanercept (TNF inhibitor) and methotrexate that suppresses tumor necrosis factor and reduces immune-mediated inflammation.
ETN+MTX is a combination therapy of etanercept (TNF inhibitor) and methotrexate that suppresses tumor necrosis factor and reduces immune-mediated inflammation. Used for Rheumatoid arthritis, Other TNF-responsive inflammatory conditions.
At a glance
| Generic name | ETN+MTX |
|---|---|
| Also known as | etanercept and methotrexate |
| Sponsor | Japan Biological Agent Study Integrated Consortium |
| Drug class | TNF inhibitor + DMARD combination |
| Target | TNF-α receptor; dihydrofolate reductase |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor-alpha, a key inflammatory cytokine. Methotrexate is a disease-modifying antirheumatic drug (DMARD) that inhibits dihydrofolate reductase and reduces cellular proliferation and immune activation. The combination provides synergistic anti-inflammatory and immunosuppressive effects.
Approved indications
- Rheumatoid arthritis
- Other TNF-responsive inflammatory conditions
Common side effects
- Infection (including serious infections)
- Injection site reactions
- Hepatotoxicity
- Bone marrow suppression
- Nausea
Key clinical trials
- Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis (PHASE4)
- Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response (PHASE3)
- Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT (PHASE2)
- STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS (PHASE3)
- Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation (PHASE3)
- Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis (PHASE3)
- Treatments Against RA and Effect on FDG-PET/CT (PHASE4)
- Etanercept and Methotrexate in Patients to Induce Remission in Early Arthritis (EMPIRE) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ETN+MTX CI brief — competitive landscape report
- ETN+MTX updates RSS · CI watch RSS
- Japan Biological Agent Study Integrated Consortium portfolio CI